Literature DB >> 17325885

EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning.

Jonathan M Cohen1, Nichola Cooper, Suparno Chakrabarti, Kirsty Thomson, Sujith Samarasinghe, David Cubitt, Cathryn Lloyd, Ann Woolfrey, Paul Veys, Persis J Amrolia.   

Abstract

The use of reduced intensity regimens has decreased early mortality following stem cell transplantation. However, the increased immunosuppression following these protocols results in profound and often prolonged lymphopenia, resulting in an increased incidence of viral reactivation. We and others have observed a high incidence of EBV viraemia and post-transplant lymphoproliferative disease (PTLD) following reduced-intensity conditioning regimens, reflecting the delayed recovery of EBV-specific immunity after such transplants. The clinical and histological features at presentation are similar to that seen after conventional intensity conditioning. Given the increasing use of reduced intensity conditioning (RIC) transplants, we review the risk factors for EBV related disease following transplantation with RIC, the potential for pre-emptive therapy of PTLD based on monitoring EBV viraemia and management options in such patients.

Entities:  

Mesh:

Year:  2007        PMID: 17325885     DOI: 10.1080/10428190601059837

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  18 in total

Review 1.  Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation.

Authors:  Francesco Pegoraro; Claudio Favre
Journal:  Ann Hematol       Date:  2021-02-06       Impact factor: 3.673

2.  Adoptive cellular therapy with T cells specific for EBV-derived tumor antigens.

Authors:  John Craddock; Helen E Heslop
Journal:  Update Cancer Ther       Date:  2008-03

Review 3.  How I treat EBV lymphoproliferation.

Authors:  Helen E Heslop
Journal:  Blood       Date:  2009-09-01       Impact factor: 22.113

Review 4.  Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant.

Authors:  Rayne H Rouce; Chrystal U Louis; Helen E Heslop
Journal:  Curr Opin Hematol       Date:  2014-11       Impact factor: 3.284

5.  Prospective evaluation of epstein-barr virus reactivation after stem cell transplantation: association with monoclonal gammopathy.

Authors:  Patrizia Chiusolo; Elisabetta Metafuni; Paola Cattani; Nicola Piccirillo; Rosaria Santangelo; Stefania Manzara; Silvia Bellesi; Teresa De Michele; Giuseppe Leone; Simona Sica
Journal:  J Clin Immunol       Date:  2010-08-25       Impact factor: 8.317

Review 6.  Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines.

Authors:  Jan Styczynski; Walter van der Velden; Christopher P Fox; Dan Engelhard; Rafael de la Camara; Catherine Cordonnier; Per Ljungman
Journal:  Haematologica       Date:  2016-07       Impact factor: 9.941

Review 7.  Immune deficits in allogeneic hematopoietic stem cell transplant (HSCT) recipients.

Authors:  Muhammad A Mir; Minoo Battiwalla
Journal:  Mycopathologia       Date:  2009-01-21       Impact factor: 2.574

8.  Epstein-barr virus related lymphoproliferations after stem cell transplantation.

Authors:  Simona Sica; Elisabetta Metafuni; Silvia Bellesi; Patrizia Chiusolo
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-14       Impact factor: 2.576

9.  Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation: multifactorial impact on transplant outcomes.

Authors:  Yuhua Ru; Xiang Zhang; Tiemei Song; Yiyang Ding; Ziling Zhu; Yi Fan; Yang Xu; Aining Sun; Huiying Qiu; Zhengming Jin; Xiaowen Tang; Yue Han; Zhengzheng Fu; Suning Chen; Xiao Ma; Feng Chen; Jia Chen; Depei Wu
Journal:  Bone Marrow Transplant       Date:  2020-02-17       Impact factor: 5.483

Review 10.  Virus-specific T-cell therapies for patients with primary immune deficiency.

Authors:  Michael D Keller; Catherine M Bollard
Journal:  Blood       Date:  2020-02-27       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.